Ropivacaine

also known as Ropivicaine · ropivacaine hydrochloride · Naropin · Ropivacaine HCl · Ropivacain · Naropeine · Naropin, 0.5% Injectable Solution · PRF-110 · +19 more

Other / unclassified

Developed for: neuropathy, painful · osteoarthritis, knee · osteoarthritis, hip · breast cancer · lumbar disk disease · bone disorder · delirium · liver cancer
+72 more
· peripheral nerve lesion · rotator cuff syndrome · appendicitis · brain aneurysm · chronic pain syndrome · developmental dysplasia of the hip · gallbladder disorder · osteoarthritis · pregnancy disorder · atrial fibrillation · frozen shoulder · heart failure · large intestine disorder · local anesthetic poisoning · migraine disorder · morbid obesity · musculoskeletal system disorder · post-traumatic stress disorder · toe, misshapen · abdominal aortic aneurysm · acute pancreatitis · adolescent idiopathic scoliosis · anal fistula · ankle defects short stature · anterior cutaneous nerve entrapment syndrome · anterior deviation infundibular septum · arthropathy · benign female reproductive system neoplasm · cardiac valvular defect · cerebral palsy · cleft palate · coronary artery disorder · craniofacial and skeletal defects · cryptorchidism · digestive system disorder · disease of bone structure · epidermolysis bullosa · fetal growth restriction · headache disorder · hemorrhoid · hernia, double inguinal · myocardial infarction · myofascial pain syndrome · neoplasm of testis · nerve compression syndrome · obstetric disorder · ovarian cancer · ovarian cyst · pain agnosia · posterior dislocation of lens · postmenopausal osteoporosis · preeclampsia · respiratory paralysis · scoliosis · soft tissue neoplasm · tenosynovitis of foot and ankle · ulcer of lower limbs · urinary bladder disorder · urinary tract obstruction · urolithiasis · carpal tunnel syndrome · congenital heart malformation · ductal breast carcinoma in situ · impacted teeth, multiple · myopathy · paralytic ileus · pectus excavatum · peripheral arterial occlusive disease 1 · rheumatic disorder · temporomandibular joint disorder · thoracic outlet syndrome · uterine corpus leiomyoma
Investigated by: University of California, San Diego · Yonsei University · Beijing Tiantan Hospital · Duke University · Centre Hospitalier Universitaire, Amiens · Chuncheon Sacred Heart Hospital
+410 more
· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Nordsjaellands Hospital · Northwestern University · Nîmes University Hospital · University Hospital, Clermont-Ferrand · University of California, San Francisco · University of Florida · Zealand University Hospital · Assistance Publique - Hôpitaux de Paris · China Medical University, China · McGill University Health Centre/Research Institute of the McGill University Health Centre · McMaster University · San Gerardo Hospital · Seoul National University Hospital · Thomas Jefferson University · United States Department of Defense · University Hospital, Strasbourg, France · University of Minnesota · Virginia Commonwealth University · Ajou University School of Medicine · Asan Medical Center · AstraZeneca · Boston Children's Hospital · Cali Pharmaceuticals LLC · Centre Hospitalier Universitaire Dijon · Centre Hospitalier Universitaire Vaudois · Columbia University · Cui Xulei · Fondazione IRCCS Policlinico San Matteo di Pavia · Guangzhou General Hospital of Guangzhou Military Command · Huazhong University of Science and Technology · Institut Curie · KK Women's and Children's Hospital · Massachusetts General Hospital · Mayo Clinic · Montefiore Medical Center · Peking Union Medical College Hospital · Poznan University of Medical Sciences · St. Joseph's Healthcare Hamilton · University Hospital, Angers · University Hospital, Bordeaux · University Hospital, Geneva · University Hospital, Lille · University Hospital, Rouen · University of California, Los Angeles · University of Saskatchewan · University of Texas Southwestern Medical Center · Vinmec Healthcare System · Örebro University, Sweden · Baxter Healthcare Corporation · CMC Ambroise Paré · Carmel Medical Center · Centre Hospitalier Departemental Vendee · Daniel Hägi-Pedersen · Ewha Womans University Mokdong Hospital · Fondation Apicil · Fujian Provincial Hospital · General Hospital of Ningxia Medical University · Healthpoint Hospital · Hospices Civils de Lyon · Innovation Fund Denmark · Keimyung University Dongsan Medical Center · Lundbeck Foundation · Medical University of Silesia · Milton S. Hershey Medical Center · Naestved Hospital · Nanjing First Hospital, Nanjing Medical University · Nantes University Hospital · Ochsner Health System · Ottawa Hospital Research Institute · PHARMAFINA · PainReform LTD · Peking University First Hospital · Peking University Third Hospital · all 416 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	NAROPIN	—	2000-11-02	fda.gov ↗
Approved	US (FDA)	NAROPIN	—	1996-09-24	fda.gov ↗

Trials 493 · started per year

today

US approved 1996

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 010 trials
Phase 0	NCT06570538	Sep 2024 → May 2025 overdue	—	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	Not yet recruiting	No outcome recorded
Phase 0	NCT05824338	Aug 2024 → Jul 2025 overdue	—	Fraser Health	Recruiting	No outcome recorded
Phase 0	NCT06720285	Oct → Nov 2023	—	Universitas Airlangga	Completed	No outcome recorded
Phase 0	NCT05247255	Mar 2022 → Dec 2026 expected	—	University of California, Los Angeles	Enrolling by invitation	No outcome recorded
Phase 0	NCT03817034	Mar 2021	—	Massachusetts General Hospital	Withdrawn	No outcome recorded
Phase 0	NCT04759742	Mar 2021 → Jun 2023	—	Yanchao Yang	Completed	No outcome recorded
Phase 0	NCT04302181	Oct 2020 → Jul 2021	post-traumatic stress disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 0	NCT03906838	Jan → Nov 2020	head and neck neoplasm, substance-related disorder	University of Florida	Withdrawn	No outcome recorded Stop: Business
Phase 0	NCT02361775	Jul 2012 → Oct 2014	—	University of Minnesota	Completed	No outcome recorded
Phase 0	NCT01355757	Jun 2011 → Jan 2013	rotator cuff syndrome	St. Luke's-Roosevelt Hospital Center	Completed	No outcome recorded
Phase 110 trials · 2 missed
Phase 1	NCT06781632	Nov 2024 → Feb 2025	—	PHARMAFINA	Completed	No outcome recorded
Phase 1	NCT06095973	Oct 2023 → Sep 2024	neuropathy, painful	G2GBio, Inc.	Completed	No outcome recorded
Phase 1	NCT05343299	May 2022 → Jun 2023	—	Nîmes University Hospital	Completed	Missed primary
Phase 1	NCT05442411	Mar 2021 → Mar 2022	—	Universiti Sains Malaysia	Completed	No outcome recorded
Phase 1	NCT03805360	May 2019 → Jan 2020	—	Virginia Commonwealth University	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02801799	Oct → Nov 2016	neuropathy, painful	Nordsjaellands Hospital	Terminated	Missed primary
Phase 1	NCT02297191	Jul → Nov 2014	—	Medical University of South Carolina	Completed	No outcome recorded
Phase 1	NCT02139982	Jan 2011 → Dec 2012	—	Wenzhou Medical University	Completed	No outcome recorded
Phase 1	NCT00722709	Sep 2008 → Nov 2009	—	University of Auckland, New Zealand	Completed	No outcome recorded
Phase 1	NCT01307969	Feb → May 2007	local anesthetic poisoning	University of Campinas, Brazil	Completed	No outcome recorded
Phase 1/25 trials · 2 missed
Phase 1/2	NCT06447194	Oct 2025 → Jan 2027	intervertebral disk degenerative disorder, lumbar spinal stenosis, spondylolisthesis	University of Maryland, Baltimore	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT02624089	Jan 2016 → Jun 2017	appendicitis	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	Missed primary
Phase 1/2	NCT01866917	Apr 2013 → Apr 2016	—	Montefiore Medical Center	Terminated	Missed primary
Phase 1/2	NCT04051684	Apr → May 2013	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 1/2	NCT00910013	Apr 2006 → Mar 2008	—	Hopital de l'Enfant-Jesus	Completed	No outcome recorded
Phase 238 trials · 1 met primary · 6 missed
Phase 2	NCT05953766	Sep 2025 → Jul 2026 overdue	—	Mount Sinai Hospital, Canada	Recruiting	No outcome recorded
Phase 2	NCT07131657	Sep → Dec 2025	—	PHARMAFINA	Completed	No outcome recorded
Phase 2	NCT06574269	Sep 2024 → Jul 2026 overdue	—	TLC Biopharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 2	NCT05889741	Feb 2024 → Mar 2027 expected	post-traumatic stress disorder	The University of Texas Health Science Center at San Antonio	Recruiting	No outcome recorded
Phase 2	NCT06008795	Dec 2023 → Jan 2027 expected	acquired aneurysmal subarachnoid hemorrhage, headache disorder	University of Florida	Recruiting	No outcome recorded
Phase 2	NCT05625802	Feb 2023 → Jan 2024	urinary tract obstruction, urolithiasis	University of Michigan	Completed	No outcome recorded
Phase 2	NCT05561309	Oct 2022 → Dec 2024	—	Shanghai Hengrui Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT05411861	Jun → Sep 2022	—	Cali Pharmaceuticals LLC	Completed	No outcome recorded
Phase 2	NCT05216055	Apr → Dec 2022	large intestine disorder	University of Colorado, Denver	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT05160298	Oct 2021 → Nov 2022	—	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 2	NCT05080959	Jul → Dec 2021	hernia, double inguinal	Cali Pharmaceuticals LLC	Completed	No outcome recorded
Phase 2	NCT05355597	Jan 2021 → Mar 2025	musculoskeletal system disorder, soft tissue neoplasm	Atlantic Health System	Terminated	No outcome recorded
Phase 2	NCT05504967	Dec 2020 → Jul 2023	—	Clinical Academic Center (2CA-Braga)	Completed	No outcome recorded
Phase 2	NCT04250805	Oct 2020 → Jan 2024	cancer, eating disorder	University Hospital of Saint-Etienne	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05016180	Sep 2020 → Nov 2021	—	Tianjin Medical University General Hospital	Unknown	No outcome recorded
Phase 2	NCT04495504	Jul 2020 → Jan 2021	—	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 2	NCT04182880	Jan → Feb 2020	—	Cali Pharmaceuticals LLC	Completed	No outcome recorded
Phase 2	NCT03149783	Feb 2018 → Aug 2021	delirium, neuropathy, painful	University of Colorado, Denver	Unknown	No outcome recorded
Phase 2	NCT03974035	Jan 2018 → Jan 2020	craniofacial and skeletal defects	Servei Central d'Anestesiologia	Completed	No outcome recorded
Phase 2	NCT03349034	Sep 2017 → Sep 2019	head and neck cancer	Icahn School of Medicine at Mount Sinai	Completed	Missed primary
Phase 2	NCT03222323	Jul 2017 → Jan 2018	—	Zealand University Hospital	Unknown	Mixed
Phase 2	NCT03138668	May → Jun 2017	—	Zealand University Hospital	Completed	Missed primary
Phase 2	NCT03015532	Jan 2017 → Apr 2018	—	Heron Therapeutics	Completed	Met primary
Phase 2	NCT02884440	Nov 2016 → May 2019	spondylolisthesis	Rennes University Hospital	Completed	Missed primary
Phase 2	NCT02431065	May 2015 → May 2016	—	Chungnam National University Hospital	Unknown	No outcome recorded
Phase 2	NCT02270255	Apr 2015 → Nov 2017	leiomyoma	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 2	NCT01890408	Nov 2013 → Feb 2014	—	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 2	NCT01997593	Nov 2013 → May 2014	neoplasm of testis	Ping Yang	Completed	No outcome recorded
Phase 2	NCT01963299	Aug → Oct 2013	posterior dislocation of lens	Centre Hospitalier Universitaire Dijon	Completed	No outcome recorded
Phase 2	NCT01828788	Apr 2013 → Jan 2015	chronic bronchitis, obesity disorder	University Hospital, Clermont-Ferrand	Completed	Missed primary
Phase 2	NCT01855529	Apr 2013 → Aug 2016	—	Centre Jean Perrin	Completed	No outcome recorded
Phase 2	NCT01703351	Oct 2012 → Nov 2015	lung neoplasm	Yonsei University	Completed	No outcome recorded
Phase 2	NCT01575028	Oct 2012 → Jul 2014	appendicitis	Nationwide Children's Hospital	Terminated	No outcome recorded
Phase 2	NCT01681966	Sep 2012 → May 2016	—	PainReform LTD	Completed	No outcome recorded
Phase 2	NCT01452126	Jun → Sep 2011	—	University of New Mexico	Terminated	No outcome recorded
Phase 2	NCT01602250	Jan 2011 → Aug 2013	poisoning	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 2	NCT00980616	Sep 2009 → Sep 2010	—	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 2	NCT00210132	Oct 2003 → Jun 2006	cancer	Institut Bergonié	Completed	Missed primary

Phase 2/314 trials · 5 missed
Phase 2/3	NCT07290595	Jan 2025 → Feb 2026 overdue	hypotensive disorder	Sahiwal medical college sahiwal	Recruiting	No outcome recorded
Phase 2/3	NCT06519955	Oct 2024 → May 2026	developmental dysplasia of the hip	Michael C Willey	Completed	No outcome recorded
Phase 2/3	NCT05054179	Sep 2022 → Jan 2024	—	University of British Columbia	Unknown	Missed primary
Phase 2/3	NCT04669145	Jun 2021 → Apr 2024	musculoskeletal system disorder	Ochsner Health System	Completed	No outcome recorded
Phase 2/3	NCT04513145	Oct 2020 → Dec 2024	osteoarthritis	OrthoCarolina Research Institute, Inc.	Terminated	No outcome recorded
Phase 2/3	NCT03739021	Nov 2019 → Mar 2020 overdue	chronic pain syndrome	University of South Florida	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03260283	Aug 2017 → Nov 2018	—	Saint Savvas Anticancer Hospital	Completed	No outcome recorded
Phase 2/3	NCT03167905	Jun 2017 → Jul 2021 overdue	postpartum depression	KK Women's and Children's Hospital	Active not recruiting	Missed primary
Phase 2/3	NCT03316378	Jan 2016 → May 2018	tendinitis	Ruth Chimenti	Completed	Missed primary
Phase 2/3	NCT02617199	Nov 2015 → Dec 2016	acute pancreatitis	Hospital General Naval de Alta Especialidad - Escuela Medico Naval	Unknown	No outcome recorded
Phase 2/3	NCT03238430	May 2015 → May 2019	—	University Hospital, Lille	Completed	No outcome recorded
Phase 2/3	NCT02453516	Oct 2014 → Sep 2019	—	Women's College Hospital	Completed	Missed primary
Phase 2/3	NCT01743794	Jan 2011	—	University Hospital, Grenoble	Completed	Missed primary
Phase 2/3	NCT00586976	Jul 2005 → Jun 2007	—	Mayo Clinic	Terminated	No outcome recorded

Phase 367 trials · 4 met primary · 9 missed
Phase 3	NCT06511765	Mar → Sep 2026 overdue	lumbar disk disease	Elsan	Recruiting	No outcome recorded
Phase 3	NCT07414706	Mar 2026 → Jun 2028 expected	local anesthetic poisoning	Centre Hospitalier Universitaire, Amiens	Not yet recruiting	No outcome recorded
Phase 3	NCT07076368	Oct 2025 → Jul 2026 overdue	pregnancy disorder	University of California, San Francisco	Recruiting	No outcome recorded
Phase 3	NCT06875427	Jul 2025 → Jan 2027 expected	—	Isabella Jaramillo	Recruiting	No outcome recorded
Phase 3	NCT07561827	Jun 2025 → Jan 2027 expected	adolescent idiopathic scoliosis	University of California, San Francisco	Recruiting	No outcome recorded
Phase 3	NCT06381622	Apr → Oct 2024	—	Nordsjaellands Hospital	Completed	Met primary
Phase 3	NCT05773846	Mar 2023 → Jul 2024	toe, misshapen	PainReform LTD	Completed	No outcome recorded
Phase 3	NCT05345639	Aug 2022 → Aug 2023	—	University Hospital, Angers	Completed	No outcome recorded
Phase 3	NCT05515809	Jul 2022 → Jun 2025 overdue	—	Centre Hospitalier Universitaire, Amiens	Active not recruiting	No outcome recorded
Phase 3	NCT05463809	Jul 2022 → Jan 2023	tenosynovitis of foot and ankle	Nanjing First Hospital, Nanjing Medical University	Unknown	No outcome recorded
Phase 3	NCT05053087	Apr 2022 → Feb 2023	osteoarthritis, knee	Mayo Clinic	Completed	No outcome recorded
Phase 3	NCT04939545	Dec 2021 → Mar 2023	—	University Hospital, Basel, Switzerland	Completed	Missed primary
Phase 3	NCT04702685	Jan → May 2021	neuropathy, painful	Nazarbayev University Medical Center	Unknown	No outcome recorded
Phase 3	NCT04588389	Dec 2020 → May 2021	lumbar disk disease, substance-related disorder	University of Massachusetts, Worcester	Terminated	No outcome recorded
Phase 3	NCT04065009	Aug 2020 → Sep 2028 expected	ovarian cancer	Karolinska Institutet	Active not recruiting	Missed primary
Phase 3	NCT04011150	Aug 2020 → Dec 2025 overdue	—	KK Women's and Children's Hospital	Recruiting	No outcome recorded
Phase 3	NCT04327063	Aug 2020 → Dec 2021	breast cancer	Institut Curie	Completed	Met primary
Phase 3	NCT04222010	Jan 2020 → Feb 2023	—	Centre Hospitalier Universitaire, Amiens	Completed	Missed primary
Phase 3	NCT04473508	Nov 2019 → Jun 2021	—	Nîmes University Hospital	Completed	Missed primary
Phase 3	NCT03936387	Jul → Sep 2019	neuropathy, painful	Boston Children's Hospital	Completed	No outcome recorded
Phase 3	NCT03984656	Jun 2019 → Sep 2026 overdue	—	Centre Hospitalier Universitaire, Amiens	Recruiting	No outcome recorded
Phase 3	NCT02438852	Feb 2019 → Feb 2021	urinary bladder carcinoma	University of Southern California	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT03688269	Oct 2018 → Nov 2019	—	Centre Hospitalier Universitaire de Besancon	Completed	No outcome recorded
Phase 3	NCT03513445	Jun 2018 → Mar 2022	intervertebral disk degenerative disorder, lumbar disk disease, spondylolisthesis	University of Minnesota	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT03620136	Feb 2018 → Nov 2019	—	Hospices Civils de Lyon	Completed	Missed primary
Phase 3	NCT03084549	Oct 2017 → Nov 2020	—	Centre Hospitalier Departemental Vendee	Completed	Missed primary
Phase 3	NCT02959476	Mar 2017 → Aug 2018	neuropathy, painful	BioQ Pharma, Inc.	Completed	No outcome recorded
Phase 3	NCT02949674	Sep → Oct 2016	—	Mexican Social Security Institute	Completed	No outcome recorded
Phase 3	NCT02740127	Jun 2016 → May 2020	male reproductive organ cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT02655965	May 2016 → Nov 2019	—	Jules Bordet Institute	Completed	No outcome recorded
Phase 3	NCT02682186	Feb 2016 → Oct 2019	—	University Hospital, Montpellier	Completed	Met primary
Phase 3	NCT02506855	Jun 2015 → Jan 2016	—	University of Mississippi Medical Center	Withdrawn	No outcome recorded
Phase 3	NCT02541552	Apr → Nov 2015	—	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 3	NCT02408393	Mar 2015 → Jul 2018	breast cancer	Institut Curie	Completed	Missed primary
Phase 3	NCT02423876	Mar 2015 → Jan 2022	female reproductive organ cancer	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 3	NCT02410317	Feb 2015 → Aug 2021	—	University Hospital, Grenoble	Completed	No outcome recorded
Phase 3	NCT02641288	Jan → Dec 2015	—	Hospital General Universitario Elche	Completed	No outcome recorded
Phase 3	NCT02540070	Aug 2014 → Dec 2017	osteoarthritis, knee	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	No outcome recorded
Phase 3	NCT02154763	Jul 2014 → Jan 2015	—	Ottawa Hospital Research Institute	Completed	Missed primary
Phase 3	NCT02353702	Jul 2014 → Jun 2017	—	University Hospital, Rouen	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02161705	Jul 2014 → Apr 2018	—	Johns Hopkins University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02568995	May 2014 → Sep 2016	—	Örebro University, Sweden	Completed	No outcome recorded
Phase 3	NCT02112370	May 2014 → May 2016	goiter, thyroid tumor	Seoul National University Hospital	Completed	Met primary
Phase 3	NCT01999153	Dec 2013 → Oct 2018	—	University Hospital, Rouen	Completed	No outcome recorded
Phase 3	NCT02444897	Sep 2013 → Dec 2014	gastric cancer	Keimyung University Dongsan Medical Center	Completed	No outcome recorded
Phase 3	NCT02002663	Aug 2013 → Jun 2016	—	Fondazione IRCCS Policlinico San Matteo di Pavia	Completed	No outcome recorded
Phase 3	NCT02525211	Oct 2012 → Apr 2017	breast cancer	Institut Paoli-Calmettes	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01592630	May 2012 → May 2013	large intestine disorder	Stamford Hospital	Withdrawn	No outcome recorded
Phase 3	NCT01623635	Feb → Sep 2012	—	University of Padova	Unknown	No outcome recorded
Phase 3	NCT02264821	Feb 2012 → Aug 2014	—	Dr Madeleine Wilwerth	Completed	No outcome recorded
Phase 3	NCT02184559	Feb 2012 → Aug 2014	—	Assistance Publique Hopitaux De Marseille	Unknown	No outcome recorded
Phase 3	NCT01432496	Sep 2011 → Dec 2012	—	San Gerardo Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01318161	Mar 2011 → Dec 2020	colorectal cancer	Örebro University, Sweden	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01367418	Sep 2010 → Mar 2012	prostate cancer	Örebro University, Sweden	Completed	No outcome recorded
Phase 3	NCT01142622	Apr 2010 → Dec 2012	ovarian cyst	San Gerardo Hospital	Completed	No outcome recorded
Phase 3	NCT01077752	Feb 2010 → Jun 2012	neuropathy, painful	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00927979	Jun 2009 → Jul 2010	—	Carmel Medical Center	Completed	No outcome recorded
Phase 3	NCT00802048	Feb 2009 → Jan 2010	—	University Hospital, Bordeaux	Terminated	No outcome recorded
Phase 3	NCT00825422	Jan 2009 → Apr 2010	—	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 3	NCT01512914	May 2008 → Sep 2009	—	San Gerardo Hospital	Completed	No outcome recorded
Phase 3	NCT01248819	Apr 2008 → May 2009	gallbladder disorder	San Gerardo Hospital	Completed	No outcome recorded
Phase 3	NCT00620490	Mar 2008 → Feb 2009	—	University Hospital, Strasbourg, France	Completed	Missed primary
Phase 3	NCT00433316	Feb → Oct 2007	—	Carmel Medical Center	Completed	No outcome recorded
Phase 3	NCT00427947	Dec 2006 → Apr 2009	—	University Hospital, Bordeaux	Terminated	No outcome recorded
Phase 3	NCT00547989	Oct 2006 → Dec 2010	breast cancer	Maastricht University Medical Center	Completed	No outcome recorded
Phase 3	NCT00358280	Apr → Sep 2006	—	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00197340	Aug 2003 → Dec 2006	fetal growth restriction, preeclampsia	Hadassah Medical Organization	Completed	No outcome recorded

Phase 4178 trials · 19 met primary · 18 missed
Phase 4	NCT07497737	Dec 2026 → Apr 2027 expected	frozen shoulder	University Hospitals Cleveland Medical Center	Not yet recruiting	No outcome recorded
Phase 4	NCT07624916	Jun 2026 → Mar 2028 expected	colorectal cancer	Tri-Service General Hospital (TSGH)	Not yet recruiting	No outcome recorded
Phase 4	NCT06054750	Jan → Feb 2026	osteoarthritis, knee	McMaster University	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT07349810	Jan → Jun 2026 overdue	—	Rutgers, The State University of New Jersey	Recruiting	No outcome recorded
Phase 4	NCT07116343	Oct 2025 → Sep 2027 expected	coronary artery disorder, heart valve disorder	Saint Petersburg State University, Russia	Recruiting	No outcome recorded
Phase 4	NCT05642026	Sep 2025 → Feb 2027 expected	—	Zachary Warriner	Recruiting	No outcome recorded
Phase 4	NCT07145775	Sep 2025 → Jan 2026	—	Peking University First Hospital	Completed	No outcome recorded
Phase 4	NCT07076069	Jul 2025 → Jun 2028 expected	rotator cuff syndrome	Montefiore Medical Center	Recruiting	No outcome recorded
Phase 4	NCT07866443	Mar → Dec 2025	myofascial pain syndrome	National and Kapodistrian University of Athens	Completed	No outcome recorded
Phase 4	NCT06950372	Feb 2025 → Apr 2026	—	Oslo University Hospital	Completed	No outcome recorded
Show all 178 trials opens the full record — a long page
Phase not applicable170 trials · 10 met primary · 8 missed
—	NCT07839039	Nov 2026 → Dec 2028 expected	bladder exstrophy	Giorgio Veneziano	Not yet recruiting	No outcome recorded
—	NCT07853482	Oct 2026 → May 2027 expected	—	Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog	Not yet recruiting	No outcome recorded
—	NCT07848113	Oct 2026 → Oct 2027 expected	delirium, peripheral arterial disease	Assiut University	Not yet recruiting	No outcome recorded
—	NCT07603921	Sep 2026 → May 2027 expected	—	Beijing Tiantan Hospital	Recruiting	No outcome recorded
—	NCT07591233	Jun 2026 → Mar 2027 expected	gallbladder disorder	Beijing Tiantan Hospital	Recruiting	No outcome recorded
—	NCT07562945	May → Oct 2026 expected	breast cancer	Aldy Aldy	Not yet recruiting	No outcome recorded
—	NCT07294755	Apr 2026 → May 2027 expected	—	Chinese PLA General Hospital	Not yet recruiting	No outcome recorded
—	NCT07452471	Feb 2026 → Feb 2027 expected	gastric cancer	Gyeong-Jo Byeon, MD, PhD	Not yet recruiting	No outcome recorded
—	NCT07353047	Feb → Sep 2026 overdue	—	Northern Jiangsu People's Hospital	Not yet recruiting	No outcome recorded
—	NCT07209345	Oct 2025 → Oct 2026 expected	—	Beijing Tiantan Hospital	Recruiting	No outcome recorded
Show all 170 trials opens the full record — a long page
Phase not stated1 trial
—	NCT06925789	Jun 2025 → Dec 2027	—	Milton S. Hershey Medical Center	Withdrawn	No outcome recorded
Comparator or background therapy635 trials
Phase 0	NCT07108465 Comparator	Jul → Sep 2025 overdue	impacted teeth, multiple	Henrique Tedesco	Recruiting	No outcome recorded
Phase 0	NCT06299137 Background	Jul 2024 → Dec 2025	substance-related disorder	Rhode Island Hospital	Completed	No outcome recorded
Phase 0	NCT04916691 Background	May 2021 → Aug 2022	—	Mayo Clinic	Completed	No outcome recorded
Phase 0	NCT04413799 Comparator	Sep 2020 → Dec 2024	—	George Washington University	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT04263064 Comparator	Mar 2020 → Aug 2022	—	Medical University of South Carolina	Completed	No outcome recorded
Show all 635 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2026-06-25	PainReform LTD	Results PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark prf-tech.com ↗ today announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study.
2025-12-24	G2GBio, Inc.	Results 지투지바이오 '수술 후 통증치료제' 개발 순항 g2gbio.com ↗ CSR 결과에 따르면 건강한 성인 남성 40명을 대상으로 GB-6002 단회 투여에 대한 안전성∙내약성∙약동학 등을 평가한 결과, 중증 이상반응이나 연구 중단 사례는 발생하지 않았다.
2024-08-07	PainReform LTD	Results PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses prf-tech.com ↗ This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110’s promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold.
2023-09-21	G2GBio, Inc.	Regulatory 비마약성 진통제로 3일 이상 약효...새내기 벤처가 "일낸다" g2gbio.com ↗ 21 일 식품의약품안전처에 따르면 , 지투지바이오는 'GB6002' 임상시험 1 상을 승인받았다 .
2023-05-18	PainReform LTD	Results PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery prf-tech.com ↗ Cmax value among all of the 15 patients, was approximately 10% of the safety window set by FDA.
2017-03-14	BioQ Pharma, Inc.	Regulatory BioQ Pharma Receives Australian Regulatory Approval for Ropivacaine ReadyFusOR bioqpharma.com ↗ BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Ropivacaine ReadyFusOR for the treatment of post-surgical pain in adults via continuous peripheral nerve block and continuous wound infiltration.

All press releases naming this drug 11 releases

Date	Issuer	Release
2026-06-25	PainReform LTD	PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark prf-tech.com ↗
2025-12-24	G2GBio, Inc.	지투지바이오 '수술 후 통증치료제' 개발 순항 g2gbio.com ↗
2025-10-23	Glenmark Pharmaceuticals Ltd. India	Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials glenmarkpharma.com ↗
2024-12-17	Meitheal Pharmaceuticals, Inc.	Ropivacaine Hydrochloride Injection, USP All Sizes Now Available meithealpharma.com ↗
2024-08-07	PainReform LTD	PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses prf-tech.com ↗
2023-09-21	G2GBio, Inc.	비마약성 진통제로 3일 이상 약효...새내기 벤처가 "일낸다" g2gbio.com ↗
2023-05-18	PainReform LTD	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery prf-tech.com ↗
2017-09-05	BioQ Pharma, Inc.	Cooper Pharma and BioQ Pharma Enter into Strategic Partnership for Ropivacaine ReadyfusOR in Morocco bioqpharma.com ↗
2017-03-14	BioQ Pharma, Inc.	BioQ Pharma Receives Australian Regulatory Approval for Ropivacaine ReadyFusOR bioqpharma.com ↗
2016-01-06	BioQ Pharma, Inc.	BioQ Pharma and Cipla Enter Into an Agreement to Commercialize BioQ’s Ropivacaine Infusion System in India bioqpharma.com ↗
2014-07-31	BioQ Pharma, Inc.	Cipla and BioQuiddity announce EU Commercial Partnership for Ready-to-Use Ropivacaine Infusion Product for Post-Surgical Pain Management bioqpharma.com ↗

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 1,133 sources stand behind the page.

Field	Value	Cited text
Known as	ropivacaïne	“The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm...” NCT06614257 ↗ 1082 “This double-blind, multicenter, randomized, controlled trial study was designed to compare the pharmacokinetics of continuous thoracic epidural infusion of levobupivacaine...” PMID 25977992 ↗ Aug 2015 “Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along...” NCT03175081 ↗ “This study is to examine the efficacy of continuously via surgically placed intercostal catheter administered ropivacaine at a flow rate of 6-8 ml/h of 2 mg/ml on...” NCT04939545 ↗ “The administered anesthetic mixture will include a fixed dose of fentanyl (15 μg), a variable dose of ropivacaine based on the parturient's somatometric characteristics, and a...” NCT07023497 ↗ “Patient will be given a peripheral nerve block from their treating anesthesiologist before the operation (in the OR) with an conventional ultrasound guided femoral and sciatic...” NCT04697537 ↗ “Following successful catheterization and confirmation of proper placement, a continuous intraoperative infusion of 0.25% ropivacaine was administered via the epidural route to...” NCT07097220 ↗ “Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to...” NCT06068166 ↗ “the intervention group (BRA-CLO) will receive bilateral RSB with a solution containing 8 mL of lidocaine 2%, 8 mL of ropivacaine 1%, and clonidine 75 mcg, diluted in 0.9%...” NCT07062497 ↗ “A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL...” NCT03860974 ↗ “A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the...” NCT02682498 ↗ Show 1,072 more sources
Known as	GB-6002	“This study is to evaluate the safety and tolerability of single dose of GB-6002 (Ropivacaine) Local Infiltration in healthy male Adults.” NCT06095973 ↗
Known as	Nai Le Pin	“15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden)” NCT07209345 ↗
Known as	Naropeine	“Ropivacaine 500mg/100ml Naropeine” NCT02080728 ↗ 1 “Naropeine (Ropivacaine)” NCT00724685 ↗
Known as	Naropin	“As part of abdominal surgery, local anesthetics (Naropin (Ropivacaine)) are generally administered in the end of surgery to reduce postoperative pain and promote recovery of...” NCT02819544 ↗ 16 “Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - "Ropivacaine Infusion treatment arm"” NCT02959476 ↗ “Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane” NCT03628040 ↗ “Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.” NCT05205720 ↗ “4ml of 0.25% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space.” NCT07079436 ↗ “ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery” NCT06382285 ↗ “Ropivacaine Hydrochloride 10 MG/ML [Naropin]” NCT06006026 ↗ “Naropin” NCT05972018 ↗ NCT03838133 ↗ NCT04551924 ↗ NCT03591146 ↗ Show 6 more sources
Known as	Naropin (ropivacaine hcl)	“Naropin (ropivacaine hcl)” NCT01556724 ↗
Known as	Naropin injection	“Active Comparator: Naropin injection(Ropivacaine hydrochloride), single dose.” NCT06095973 ↗
Known as	Naropin, 0.5% Injectable Solution	“Naropin, 0.5% Injectable Solution” NCT04551924 ↗ 1 “Naropin, 0.5% Injectable Solution” NCT03838133 ↗
Known as	PRF-110	“PRF-110 is a viscous, yellowish clear oily solution of ropivacaine intended for administration into surgical sites to provide post-operative analgesia.” NCT05773846 ↗ 1 “PRF110- oily solution (Ropivacaine)” NCT01681966 ↗
Known as	Product name: Ropivacain "Fresenius Kabi"	“Product name: Ropivacain "Fresenius Kabi"” NCT02242591 ↗
Known as	Raropin	“0.375%ropivacaine (Raropin) 25ml will be given” NCT04266236 ↗
Known as	Ropimol	“Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm” NCT03293472 ↗
Known as	Ropivacain	“Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain).” NCT02132065 ↗ 7 “A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control” NCT01211431 ↗ “Ropivacain” NCT01025102 ↗ NCT05648266 ↗ NCT07350252 ↗ NCT05693454 ↗ NCT02805582 ↗ NCT06230081 ↗
Known as	Ropivacain Fresenius	“Ropivacain Fresenius 0.2% is a solution for infusion/ injection and will be continuously administered with an elastomer pump through the surgically placed intercostal catheter...” NCT04939545 ↗
Known as	ROPIVACAIN Sintetica	“Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)” NCT02414373 ↗
Known as	Ropivacaine 0.75% :( Naropeine 7.5mg/ml, AstraZeneca)	“Ropivacaine 0.75% :( Naropeine 7.5mg/ml, AstraZeneca)” NCT01558713 ↗
Known as	Ropivacaine = Narop	“Ropivacaine = Narop” NCT01367418 ↗
Known as	RopivacaIne chlorhydrate	“Drug: RopivacaIne chlorhydrate” NCT02527577 ↗
Known as	Ropivacaine HCl	“Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml” NCT02944526 ↗ 9 “local anaesthetic injection of ropivacaine HCl” NCT05813847 ↗ “Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)” NCT03696095 ↗ “Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc” NCT03506620 ↗ “Ropivacaine Hcl 0.5% Injection 40 mL” NCT03405922 ↗ “Ropivacaine Hcl 0.2% Inj Vil 10Ml” NCT04062045 ↗ “Ropivacaine Hcl 0.5% Inj Vil 30Ml” NCT03502889 ↗ “Drug: Ropivacaine HCL” NCT07092566 ↗ “Drug: Ropivacaine HCL” NCT03149783 ↗ NCT02679560 ↗
Known as	Ropivacaine HCL Injection	“Ropivacaine HCL Injection” NCT06574269 ↗
Known as	ropivacaine HCl Injection, USP	“Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - "Ropivacaine Infusion treatment arm"” NCT02959476 ↗
Known as	ropivacaine hydrochloride	“solution containing 200 mg of ropivacaine hydrochloride (10mg/ml Kabi Fresenius Kabi Norway AS),150 mg if the patient weight was below 65kg” NCT05248724 ↗ 19 “To determine the median effective concentration of ropivacaine hydrochloride for ultrasound-guided supraclavicular brachial plexus block.” NCT02323282 ↗ “Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.” NCT04827030 ↗ “Ropivacaine hydrochloride injection, 0.375% solution, administered as a single dose via ultrasound-guided nerve block.” NCT07771829 ↗ “0.5% ropivacaine hydrochloride was injected locally around the incision before the surgical incision was closed.” NCT07353307 ↗ “0.5% ropivacaine hydrochloride RSB preoperatively and saline RSB postoperatively” PMID 29426287 ↗ Feb 2018 “Active Comparator: Naropin injection(Ropivacaine hydrochloride), single dose.” NCT06095973 ↗ “stellate-ganglion block with 0.25% ropivacaine hydrochloride” NCT02651519 ↗ “intrapleural block with ropivacaine hydrochloride injection” NCT07294755 ↗ “Ropivacaïne Hydrochloride by Erector Spinae block” NCT04827030 ↗ “Ropivacaine Hydrochloride 10 MG/ML [Naropin]” NCT06006026 ↗ Show 9 more sources
Known as	Ropivacaine Hydrochloride Injection , Naropin , AstraZeneca AB, Sweden	“Ropivacaine Hydrochloride Injection , Naropin , AstraZeneca AB, Sweden” NCT07079436 ↗
Known as	Ropivacaine Kabi	“or Ropivacaine Kabi (Ropivacaine Kabi) (Ropivacaine) Solution for injection 7.5 mg / ml” NCT03302689 ↗
Known as	Ropivacaine Monohydrochloride	“Drug: Ropivacaine Monohydrochloride” NCT02944526 ↗
Known as	Ropivacane	“To Compare Post-op Analgesic Effectiveness of Ropivicaine+Dexamethasone and Ropivacane+Dexmetomidine in TAP Block in Stoma Reversal Under GA in Terms of Duration of Analgesia.” NCT07368075 ↗
Known as	Ropivicaine	“Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made...” NCT01667445 ↗ 27 “To Compare Post-op Analgesic Effectiveness of Ropivicaine+Dexamethasone and Ropivacane+Dexmetomidine in TAP Block in Stoma Reversal Under GA in Terms of Duration of Analgesia.” NCT07368075 ↗ “Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection” NCT03201809 ↗ “The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.” NCT05288725 ↗ “Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control.” NCT03540095 ↗ “Subject will receive an interscalene block with Ropivicaine 0.5% (20cc)” NCT04364867 ↗ “0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate” NCT02423876 ↗ “using 25 ml of 0.5% Ropivicaine plus saline injection postoperative” NCT03253198 ↗ “0.5% Ropivicaine, 24.6 mL” NCT03696199 ↗ NCT00945620 ↗ NCT05355597 ↗ Show 17 more sources
Known as	Rupivacane	“The needle entry point will be anesthetized with 20 mL 0.25% Rupivacane plus dexamethasone 4 mg.” NCT07368075 ↗
Action	Inhibit	“It produces effects similar to other local anaesthetics via reversible inhibition of sodium ion influx in nerve fibres.” PMID 21712863 ↗ Mar 2011
Modality	Other / unclassified	“Local anaesthetic wound infiltration” PMID 21484739 ↗ Apr 2011
Route	Other	“perineural ropivacaine” PMID 18362603 ↗ Apr 2008